Journal
NANOMEDICINE
Volume 6, Issue 1, Pages 55-68Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.10.99
Keywords
cancer; HK97; protein conjugation; targeted cellular entry; transferrin; viral nanoparticles
Funding
- American Heart Association
- NIH [K99EB009105, R01CA112075, 2R01-AI40101]
- NATIONAL CANCER INSTITUTE [R01CA112075] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040101] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [K99EB009105, R00EB009105] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Aims: Next-generation targeted nanodevices are currently under development for imaging and therapeutic applications. We engineered HK97 viral nanoparticles (VNPs) for tumor cell-specific targeting. Methods: A combination of genetic and chemical engineering methods were developed and applied to generate dual-labeled HK97 cysteine mutant particles displaying transferrin and fluorescent labels. The targeting properties of transferrin-conjugated VNPs were evaluated by in vitro experiments using different cancer cell lines. Results: We found that HK97-tranferrin formulations were indeed targeted to cancer cells in vitro via the transferrin receptor. These studies highlight the utility and facilitate the further development of HK97-based VNPs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available